Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × NSCLC × tipifarnib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 3 Leukemia, Myeloid, Acute 3 Squamous Cell Carcinoma of Head and Neck 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma 2 Head and Neck Neoplasms 2 Pancreatic Neoplasms 1 NSCLC 1 Lymphoma, Extranodal NK-T-Cell 1 Leukemia, Myelomonocytic, Chronic 1 Hereditary Sensory and Autonomic Neuropathies 1 Breast Neoplasms 1 Advanced Solid Tumor 1

Interventions

Carboplatin 6 aflutinib 5 osimertinib 4 Pemetrexed 4 Gefitinib 4 HM781-36B 3 rezivertinib 2 Paclitaxel 2 HMPL-013 2 Cisplatin 2 Albumin-Bound Paclitaxel 2 tipifarnib 1 sulindac sulfone 1 spartalizumab 1 pembrolizumab 1 icotinib 1 aumolertinib 1 apatinib 1 Vinorelbine 1 Taxes 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Clinical Trials, Phase I as Topic 1 Cetuximab 1 CP protocol 1 Bortezomib 1 BID protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡